Modification of hTERT Expression for the Treatment of Solid TumorsTechnology #ua17-199
Questions about this technology? Ask a Technology Manager
- Laurence Hurley Professor, Pharmacology & Toxicology
- Andrew Kraft Professor, Medicine
- Jin Song assistant professor, Cellular & Molecular Medicine
- Vijay Gokhale Senior Research Scientist, BIO5
- Managed By
- Rakhi Gibbons Asst. Director, Life Sciences (520) 626-6695
Title: Modification of hTERT Expression for the Treatment of Solid Tumors
Invention: This invention is a synthetic compound intended to selectively kill hTERT prostate cancer cells through targeting the G-quadruplex, leaving normal prostate cells intact.
Background: Studies predict that a total of 27,000 Americans will die from Metastatic Prostate Cancer (PCa). PCa is commonly treated with a combination of hormone therapies and chemotherapy. Unfortunately hormone therapy loses effectiveness over time. This invention aims to satisfy the unmet need for long term treatment of cancer types containing hTERT cells.
- Cancer treatment (hormone and chemotherapy)
- 10,000 times more effective on Taxotere resistant prostate cancer cells